Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Public ClinicalTrials.gov record NCT00464646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate: * How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors * Side effects from adding bevacizumab to chemotherapy and trastuzumab * Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart * If receiving bevacizumab will have any effect on how patients recover from surgery
Study identification
- NCT ID
- NCT00464646
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Epirubicin Drug
- Cyclophosphamide Drug
- Docetaxel Drug
- Trastuzumab Drug
- Bevacizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2007 (Type not available)
- Primary completion
- Dec 2009 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Oct 25, 2021
2007 – 2014
United States locations
- U.S. sites
- 35
- U.S. states
- 21
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute- Huntsville | Huntsville | Alabama | 35801 | — |
| Kaiser Permanente-San Diego | San Diego | California | 92120 | — |
| Kaiser Permanente-Vallejo | Vallejo | California | 94589 | — |
| CCOP, Colorado Cancer Research Program, Inc. | Denver | Colorado | 80224 | — |
| Baptist Regional Cancer Institute | Jacksonville | Florida | 32207 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| CCOP, Central Illinois | Springfield | Illinois | 62526 | — |
| CCOP, Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| NortonHealtcare Inc. | Louisville | Kentucky | 40202 | — |
| CCOP, Grand Rapids Clnical Oncology Program | Grand Rapids | Michigan | 49503 | — |
| CCOP, Michigan Cancer Research Consortium | Grosse Pointe Woods | Michigan | 48236 | — |
| CCOP, Kalamazoo, MI | Kalamazoo | Michigan | 49007 | — |
| Michigan State University - Breslin Cancer Center | Lansing | Michigan | 48910 | — |
| CCOP, Metro-Minnesota | Minneapolis | Minnesota | 55416 | — |
| CCOP, Cancer Research for the Ozarks | Springfield | Missouri | 65804 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University Hospital and Medical Center - SUNY | Stony Brook | New York | 11794 | — |
| CCOP, Southeast Cancer Control Consortium | Charlotte | North Carolina | 28203 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Aultman Hospital | Canton | Ohio | 44710 | — |
| Case Western Reserve/University Hospitals-Ireland Cancer Cntr. | Cleveland | Ohio | 44106 | — |
| CCOP, Dayton, OH | Dayton | Ohio | 45429 | — |
| CCOP, Columbia River Oncology | Portland | Oregon | 97225 | — |
| Kimmel Cancer Center at Jefferson | Philadelphia | Pennsylvania | 19107 | — |
| Albert Einstein Healthcare Network | Philadelphia | Pennsylvania | 19141-3098 | — |
| Allegheny General Hospital/Allegheny-Singer Research Institute | Pittsburgh | Pennsylvania | 15212 | — |
| NSABP Foundation, Inc. | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Mercy Hospital | Scranton | Pennsylvania | 18501 | — |
| CCOP, Upstate Carolina | Spartanburg | South Carolina | 29303 | — |
| Joe Arrington Cancer Research & Treatment Center | Lubbock | Texas | 79410 | — |
| CCOP, Scott and White Memorial Hospital | Temple | Texas | 76508 | — |
| MBCCOP, Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
| CCOP, Marshfield Clinic | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00464646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00464646 live on ClinicalTrials.gov.